SK pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors

February 3, 2020

Biotechnology

Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

SK Capital Acquires Catalent's Blow‑Fill‑Seal Sterile CDMO Business (Woodstock Sterile Solutions)

March 31, 2021

Pharmaceuticals

Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.

SHS Capital and ING Corporate Investments Acquire Majority Stake in CAM Bioceramics

July 7, 2023

Medical Devices

German healthcare specialist investor SHS Capital, together with ING Corporate Investments and several co-investors, acquired a majority stake in CAM Bioceramics B.V., a Leiden-based contract development and manufacturing organization (CDMO) for orthobiologic calcium phosphate solutions. Existing owners rolled over a significant stake and management remains in place; the transaction aims to strengthen the business and accelerate investment in people, capabilities and customer partnerships to drive growth.

Genezen Acquires uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

July 1, 2024

Biotechnology

Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.